On Friday, Lyra Therapeutics Inc (NASDAQ: LYRA) was 3.90% up from the session before settling in for the closing price of $0.18. A 52-week range for LYRA has been $0.16 – $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 58.51%. When this article was written, the company’s average yearly earnings per share was at -6.83%. With a float of $54.79 million, this company’s outstanding shares have now reached $57.21 million.
Let’s determine the extent of company efficiency that accounts for 88 employees. In terms of profitability, gross margin is -816.72%, operating margin of -6894.43%, and the pretax margin is -6632.36%.
Lyra Therapeutics Inc (LYRA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lyra Therapeutics Inc stocks. The insider ownership of Lyra Therapeutics Inc is 16.29%, while institutional ownership is 46.46%.
Lyra Therapeutics Inc (LYRA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -6.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.60% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
You can see what Lyra Therapeutics Inc (LYRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Looking closely at Lyra Therapeutics Inc (NASDAQ: LYRA), its last 5-days average volume was 4.7 million, which is a jump from its year-to-date volume of 1.73 million. As of the previous 9 days, the stock’s Stochastic %D was 17.59%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 14.60%, which indicates a significant decrease from 22.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 166.18% in the past 14 days, which was higher than the 91.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2436, while its 200-day Moving Average is $1.8011. However, in the short run, Lyra Therapeutics Inc’s stock first resistance to watch stands at $0.1970. Second resistance stands at $0.2051. The third major resistance level sits at $0.2124. If the price goes on to break the first support level at $0.1816, it is likely to go to the next support level at $0.1743. Now, if the price goes above the second support level, the third support stands at $0.1662.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
There are 65,458K outstanding shares of the company, which has a market capitalization of 12.85 million. As of now, sales total 1,560 K while income totals -62,680 K. Its latest quarter income was 200 K while its last quarter net income were -11,870 K.
